Muscle‑loss risk with GLP‑1s

GLP-1 drugs help people lose weight, but some of that weight can come from lean mass — the body tissue that includes muscle, organs and water, not just fat. A 2025 meta-analysis of 36 randomized trials found lean-mass loss in most studies and a clearer drop versus placebo. (pubmed.ncbi.nlm.nih.gov) The analysis pooled 2,555 participants with type 2 diabetes, overweight or obesity and reviewed studies published through October 15, 2024. It reported that glucagon-like peptide-1 receptor agonists cut fat mass, body-fat percentage, visceral fat and subcutaneous fat, while lean mass also fell in placebo-controlled comparisons. (pubmed.ncbi.nlm.nih.gov) GLP-1 receptor agonists are medicines that mimic a gut hormone that lowers appetite and slows stomach emptying, which helps reduce calorie intake over time. A separate 2025 JAMA summary of randomized trials in people without diabetes said commercially available agents including liraglutide, semaglutide and tirzepatide produced weight losses of up to 18% after nearly 17 months. (jamanetwork.com) Lean mass is not the same thing as strength, and it is not all muscle, but it matters because it includes tissue tied to movement, balance and day-to-day function. A 2025 Nature Reviews Endocrinology comment said rapid weight loss with GLP-1 receptor agonists can come at the cost of skeletal muscle and could affect metabolic and functional outcomes. (nature.com) The new meta-analysis did not say GLP-1 drugs uniquely damage muscle in every setting. It found no significant lean-mass difference when the comparison group used oral diabetes drugs, insulin or lifestyle intervention, and it reported no difference in lean-mass percentage overall. (pubmed.ncbi.nlm.nih.gov) That distinction matters because weight loss itself often reduces lean mass, even without medication. A 2024 review in Diabetes, Obesity and Metabolism said GLP-1 receptor agonists induce lean-mass loss, but caloric restriction and bariatric surgery do too, and the paper focused on ways to limit that loss during treatment. (pmc.ncbi.nlm.nih.gov) One strategy under study is exercise, especially resistance training, which means working muscles against load with weights, machines or bands. In a 2021 New England Journal of Medicine trial, adults with obesity who combined liraglutide with a moderate-to-vigorous exercise program maintained weight loss better than those assigned to either strategy alone or to placebo after an initial low-calorie diet. (nejm.org) Protein intake is the other recurring recommendation, because muscle needs amino acids to rebuild while body weight is falling. The Endocrine Society said in a July 12, 2025 meeting release that a small semaglutide study found women and older adults had higher muscle-loss risk, while higher protein intake appeared protective. (endocrine.org) Researchers are now testing those ideas directly in people starting these drugs. A ClinicalTrials.gov listing updated March 3, 2026 describes a trial designed to see whether resistance exercise and protein intake can preserve lean mass and physical function during semaglutide or tirzepatide therapy. (clinicaltrials.gov) For patients and prescribers, the current evidence points to a narrower question than “Do GLP-1s work?” They do; the live question is how much of the weight lost is fat versus lean tissue, and whether exercise and protein can shift that balance. (pubmed.ncbi.nlm.nih.gov)